Department of Urology, Institute of Urologic Oncology (IUO), David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Department of Urology, University Hospital Bicetre, APHP, University Paris-Saclay, Le Kremlin Bicetre, France.
Cancer Invest. 2024 Jan;42(1):97-103. doi: 10.1080/07357907.2024.2308172. Epub 2024 Feb 5.
Approximately 65% of renal cell carcinomas (RCC) are diagnosed at a localized stage. We investigated the chromosome 5q gain impact on disease-free survival (DFS) in RCC patients. Overall, 676 patients with stages 1-2 RCC and having cytogenetic analysis were included. Gain of 5q was observed in 108 patients, more frequently in clear cell (ccRCC) than non-clear cell tumors. Gain of 5q is likely an independent prognostic factor since the concerned patients had a decreased recurrence risk in stages 1-2 RCC, confirmed in multivariable analysis. Detecting 5q gain could enhance recurrence risk assessment, allowing tailored post-surgery surveillance, and reducing unnecessary treatments.
大约 65%的肾细胞癌（RCC）在局部阶段被诊断出来。我们研究了染色体 5q 增益对 RCC 患者无病生存（DFS）的影响。共有 676 名 1-2 期 RCC 患者和细胞遗传学分析患者被纳入。在 108 例患者中观察到 5q 增益，在透明细胞（ccRCC）中比非透明细胞肿瘤更常见。5q 增益很可能是一个独立的预后因素，因为在 1-2 期 RCC 中，受影响的患者复发风险降低，这在多变量分析中得到了证实。检测 5q 增益可以增强复发风险评估，从而实现术后监测的个体化，并减少不必要的治疗。
